Immunotherapy for Ovarian Cancer
详细信息 查看全文
- 作者：Justin M. Drerup BS (1) (2)
Yang Liu BS (2) (3)
Alvaro S. Padron PhD (2)
Kruthi Murthy MS (2)
Vincent Hurez PhD ; DVM (2)
Bin Zhang MD ; PhD (4)
Tyler J. Curiel MD ; MPH (1) (2) (5)
1. Department of Cellular and Structural Biology ; School of Medicine ; University of Texas Health Science Center ; San Antonio ; TX ; 78229 ; USA
2. Department of Medicine ; School of Medicine ; University of Texas Health Science Center ; San Antonio ; TX ; 78229 ; USA
3. Department of Clinical Medicine ; Xiangya School of Medicine ; Central South University ; Changsha ; Hunan ; 410013 ; People鈥檚 Republic of China
4. Robert H. Lurie Comprehensive Cancer Center ; Department of Medicine-Division of Hematology/Oncology ; Northwestern University Feinberg School of Medicine ; Chicago ; IL ; 60611 ; USA
5. Adult Cancer Program ; Cancer Therapy and Research Center ; University of Texas Health Science Center ; 8403 Floyd Curl Drive MC8252 ; San Antonio ; TX ; 78229 ; USA - 关键词：Ovarian cancer ; Immune therapy ; Cancer vaccine ; Monoclonal antibody ; Early phase clinical trials ; Oncolytic virus ; Radioimmunotherapy ; CAR T cell ; Adoptive immunotherapy
- 刊名：Current Treatment Options in Oncology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：16
- 期：1
- 全文大小：285 KB
- 参考文献：1. Erickson, BK, Conner, MG, Landen, CN (2013) The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 209: pp. 409-14 CrossRef
2. Ioannides, CG, Fisk, B, Pollack, MS, Frazier, ML, Taylor Wharton, J, Freedman, RS (1993) Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 37: pp. 413-24 CrossRef
3. Peoples, GE, Goedegebuure, PS, Smith, R, Linehan, DC, Yoshino, I, Eberlein, TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci U S A 92: pp. 432-6 CrossRef
4. Wagner, U, Schlebusch, H, Kohler, S, Schmolling, J, Grunn, U, Krebs, D (1997) Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 16: pp. 33-40 CrossRef
5. Disis, ML, Gooley, TA, Rinn, K, Davis, D, Piepkorn, M, Cheever, MA (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20: pp. 2624-32 CrossRef
6. Knutson, KL, Schiffman, K, Cheever, MA, Disis, ML (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p 369鈥?77, results in short-lived peptide-specific immunity. Clin Cancer Res 8: pp. 1014-8
7. Qian, HN, Liu, GZ, Cao, SJ, Feng, J, Ye, X (2002) The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer 12: pp. 80-5 CrossRef
8. Curiel, TJ, Wei, S, Dong, H, Alvarez, X, Cheng, P, Mottram, P (2003) Blockade of B7-H1 improves myeloid dendritic cellmediated antitumor immunity. Nat Med 9: pp. 562-7 CrossRef
9. Curiel, TJ, Coukos, G, Zou, L, Alvarez, X, Cheng, P, Mottram, P (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: pp. 942-9 CrossRef
10. Vlad, AM, Kettel, JC, Alajez, NM, Carlos, CA, Finn, OJ (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82: pp. 249-93 CrossRef
11. Diefenbach, CS, Gnjatic, S, Sabbatini, P, Aghajanian, C, Hensley, ML, Spriggs, DR (2008) Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 14: pp. 2740-8 CrossRef
12. Coliva, A, Zacchetti, A, Luison, E, Tomassetti, A, Bongarzone, I, Seregni, E (2005) 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunol Immunother 54: pp. 1200-13 CrossRef
13. Mantovani, LT, Miotti, S, Menard, S, Canevari, S, Raspagliesi, F, Bottini, C (1994) Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer 30A: pp. 363-9 CrossRef
14. Thor, A, Gorstein, F, Ohuchi, N, Szpak, CA, Johnston, WW, Schlom, J (1986) Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J Natl Cancer Inst 76: pp. 995-1006
15. Chang, K, Pastan, I (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, ovarian cancers. Proc Natl Acad Sci U S A 93: pp. 136-40 CrossRef
16. Cheng, WF, Huang, CY, Chang, MC, Hu, YH, Chiang, YC, Chen, YL (2009) High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer 100: pp. 1144-53 CrossRef
17. Inoue, M, Ogawa, H, Nakanishi, K, Tanizawa, O, Karino, K, Endo, J (1990) Clinical value of sialyl Tn antigen in patients with gynecologic tumors. Obstet Gynecol 75: pp. 1032-6
18. Sandmaier, BM, Oparin, DV, Holmberg, LA, Reddish, MA, MacLean, GD, Longnecker, BM (1999) Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, immunization with Theratope STn-KLH cancer vaccine. J Immunother 22: pp. 54-66 CrossRef
19. Campbell, IG, Freemont, PS, Foulkes, W, Trowsdale, J (1992) An ovarian tumor marker with homology to vaccinia virus contains an IgV-like region and multiple transmembrane domains. Cancer Res 52: pp. 5416-20
20. Zhang, L, Conejo-Garcia, JR, Katsaros, D, Gimotty, PA, Massobrio, M, Regnani, G (2003) Intratumoral T cells, recurrence, survival in epithelial ovarian cancer. N Engl J Med 348: pp. 203-13 CrossRef
21. Epenetos, AA, Munro, AJ, Stewart, S, Rampling, R, Lambert, HE, McKenzie, CG (1987) Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 5: pp. 1890-9
22. Kalbasi, A, June, CH, Haas, N, Vapiwala, N (2013) Radiation and immunotherapy: a synergistic combination. J Clin Invest 123: pp. 2756-63 CrossRef
23. Bookman, MA (2012) First-line chemotherapy in epithelial ovarian cancer. Clin Obstet Gynecol 55: pp. 96-113 CrossRef
24. Beyer, M, Kochanek, M, Darabi, K, Popov, A, Jensen, M, Endl, E (2005) Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106: pp. 2018-25 CrossRef
25. Motoyoshi, Y, Kaminoda, K, Saitoh, O, Hamasaki, K, Nakao, K, Ishii, N (2006) Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 16: pp. 141-6
26. Vincent, J, Mignot, G, Chalmin, F, Ladoire, S, Brushard, M, Chevriaux, A (2010) 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 70: pp. 3052-61 CrossRef
27. Apetoh, L, Mignot, G, Pnaretakis, , Kroemer, G, Zitvogel, L (2008) Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol Med 14: pp. 141-51 CrossRef
28. Riva, P, Marangolo, M, Lazzari, S, Agostini, M, Sarti, G, Moscatelli, G (1989) Locoregional immunotherapy of human ovarian cancer: preliminary results. Int J Radiat Appl Instrum B 16: pp. 659-66 CrossRef
29. Stewart, JS, Hird, V, Snook, D, Dhokia, B, Sivolapenko, G, Hooker, G (1990) Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. J Clin Oncol 8: pp. 1941-50
30. Hird, V, Maraveyas, A, Snook, D, Dhokia, B, Soutter, WP, Meares, C (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68: pp. 403-6 CrossRef
31. Epenetos, AA, Hird, V, Lambert, H, Mason, P, Coulter, C (2000) Long term survival of patients with advanced ovarian cancer treated with term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 10: pp. 44-6 CrossRef
32. Oei, AL, Verheijen, RH, Seiden, MV, Benigno, BB, Lopes, A, Soper, JT (2007) Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 120: pp. 2710-4 CrossRef
33. Armstrong, DK, White, AJ, Weil, SC, Phillips, M, Coleman, RL (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 129: pp. 452-8 CrossRef
34. Konner, JA, Bell-McGuinn, KM, Sabbatini, P, Hensley, ML, Tew, WP, Pandit-Taskar, N (2010) Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 16: pp. 5288-95 CrossRef
35. Sehouli, J, Pietzner, K, Wimberger, P, Vergote, I, Rosenberg, P, Schneeweiss, A (2014) Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Med Oncol 31: pp. 76 CrossRef
36. Pardoll, DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: pp. 252-64 CrossRef
37. Brahmer, JR, Tykodi, SS, Chow, LQ, Hwu, WJ, Topalian, SL, Hwu, P (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: pp. 2455-65 CrossRef
38. Berek, JS (2004) Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther 4: pp. 1159-65 CrossRef
39. Ehlen, TG, Hoskins, PJ, Miller, D, Whiteside, TL, Nicodemus, CF, Schultes, BC (2005) A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 15: pp. 1023-34 CrossRef
40. Berek, J, Taylor, P, McGuire, W, Smith, LM, Schultes, B, Nicodemus, CF (2009) Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 27: pp. 418-25 CrossRef
41. Pfisterer, J, Harter, P, Simonelli, C, Peters, M, Berek, J, Sabbatini, P (2011) Abagovomab for ovarian cancer. Expert Opin Biol Ther 11: pp. 395-403 CrossRef
42. Sabbatini, P, Dupont, J, Aghajanian, C, Derosa, F, Poynor, E, Anderson, S (2006) Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 12: pp. 5503-10 CrossRef
43. Sabbatini, P, Harter, P, Scambia, G, Sehouli, J, Meier, W, Wimberger, P (2013) Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, GEICO鈥搕he MIMOSA study. J Clin Oncol 31: pp. 1554-61 CrossRef
44. Almokadem, S, Belani, CP (2012) Volociximab in cancer. Expert Opin Biol Ther 12: pp. 251-7 CrossRef
45. Bell-McGuinn, KM, Matthews, CM, Ho, SN, Barve, M, Gilbert, L, Penson, RT (2011) A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol 121: pp. 273-9 CrossRef
46. Hassan, R, Bera, T, Pastan, I (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: pp. 3937-42 CrossRef
47. Hassan, R, Cohen, SJ, Phillips, M, Pastan, I, Sharon, E, Kelley, RJ (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16: pp. 6132-8 CrossRef
48. Taniguchi, K, Karin, M (2014) IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 26: pp. 54-74 CrossRef
49. Coward, J, Kulbe, H, Chakravarty, P, Leader, D, Vassileva, V, Leinster, DA (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17: pp. 6083-96 CrossRef
50. Kryczek, I, Zou, L, Rodriguez, P, Zhu, G, Wei, S, Mottram, P (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203: pp. 871-81 CrossRef
51. Middleton, K, Jones, J, Lwin, Z, Coward, JI (2014) Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol 89: pp. 129-39 CrossRef
52. Berti, A, Boccalatte, F, Sabbadini, MG, Dagna, L (2013) Assessment of tocilizumab in the treatment of cancer cachexia. J Clin Oncol 31: pp. 2970 CrossRef
53. Maude, SL, Barrett, D, Teachey, DT, Grupp, SA (2014) Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20: pp. 119-22 CrossRef
54. Guo, Z, Cheng, D, Xia, Z, Luan, M, Wu, L, Wang, G (2013) Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med 11: pp. 215 CrossRef
55. Wei, H, Zhao, L, Li, W, Fan, K, Qian, W, Hou, S (2013) Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 8: pp. e84927 CrossRef
56. Vinay, DS, Kwon, BS (2012) Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 11: pp. 1062-70 CrossRef
57. Scott, AM, Wolchok, JD, Old, LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12: pp. 278-87 CrossRef
58. Thibodeaux SR, Curiel TJ, Thibodeaux SR, Wall S, Pandeswara SL, Daniel BJ, Drerup JM, et al. Denileukin diftitox depletes regulatory T cells without clinical benefit in advanced stage epithelial ovarian carcinoma. American Association of Immunologists 2014 Meeting; 2014. [Abstract number 1944021]. This is the first report showing that regulatory T cell depletion is possible in human ovarian cancer, with a positive clinical response in 1 patient, positive immune responses in others. However, the single-agent phase II trial in ovarian cancer failed to establish significant clinical efficacy. The related manuscript has been submitted for publication.
59. Murthy K, Curiel TJ, Sareddy G, Hurez V, Qin K, Pandeswara SL, Vadlamudi R, et al. B7-H1 blockade improves efficacy of regulatory T cell depletion as cancer immunotherapy by reducing Treg regeneration, possibly through tumor B7-H1 effects. American Association of Immunologists 2014 Meeting; 2014. [Abstract number 1944036].
60. Jin, D, Fan, J, Wang, L, Thompson, LF, Liu, A, Daniel, BJ (2010) CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 70: pp. 2245-55 CrossRef
61. Hurez, V, Daniel, BJ, Sun, L, Liu, AJ, Ludwig, SM, Kious, MJ (2012) Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. Cancer Res 72: pp. 2089-99 CrossRef
62. Lin, PY, Sun, L, Thibodeaux, SR, Ludwig, SM, Vadlamudi, RK, Hurez, VJ (2010) B7-H1-Dependent Sex-related differences in tumor immunity and immunotherapy responses. J Immunol 185: pp. 2747-53 CrossRef
63. Pestka, S, Krause, CD, Walter, MR (2004) Interferons, interferon-like cytokines, their receptors. Immunol Rev 202: pp. 8-32 CrossRef
64. Kirkwood, J (2002) Cancer immunotherapy: the interferon-alpha experience. Semin Oncol 29: pp. 18-26 CrossRef
65. Berek, JS, Hacker, NF, Lichtenstein, A, Jung, T, Spina, C, Knox, RM (1985) Intraperitoneal recombinant alpha-interferon for 鈥渟alvage鈥?immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Cancer Res 45: pp. 4447-53
66. Bezwoda, WR, Seymour, L, Dansey, R (1989) Intraperitoneal recombinant interferon-alpha 2b for recurrent malignant ascites due to ovarian cancer. Cancer 64: pp. 1029-33 CrossRef
67. Nardi, M, Cognetti, F, Pollera, CF, Giulia, MD, Lombardi, A, Atlante, G (1990) Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 8: pp. 1036-41
68. Stuart, GC, Nation, JG, Snider, DD, Thunberg, P (1993) Intraperitoneal interferon in the management of malignant ascites. Cancer 71: pp. 2027-30 CrossRef
69. Tedjarati, S, Baker, CH, Apte, S, Huang, S, Wolf, JK, Killion, JJ (2002) Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 8: pp. 2413-22
70. Metcalf, KS, Selby, PJ, Trejdosiewicz, LK, Southgate, J (1998) Culture of ascitic ovarian cancer cells as a clinically-relevant ex vivo model for the assessment of biological therapies. Eur J Gynaecol Oncol 19: pp. 113-9
71. Thibodeaux SR, Hurez V, Wall S, Pandeswara SL, Sun L, Daniel BJ, et al. Interferon-a augments the clinical efficacy of regulatory T cell depletion in ovarian cancer through direct and indirect T cell effects. American Association of Immunologists Annual Meeting. Pittsburgh, PA; 2014. [Abstract number 1943855]. This is the first report showing that combination immunotherapy could improve clinical outcomes in ovarian cancer in human patients. The related manuscript has been submitted for publication.
72. Sterman, DH, Recio, A, Haas, AR, Vachani, A, Katz, SI, Gillespie, CT (2010) A phase I trial of repeated intrapleural adenoviral-mediated interferonbeta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 18: pp. 852-60 CrossRef
73. Moserle, L, Indraccolo, S, Ghisi, M, Frasson, C, Fortunato, E, Canevari, S (2008) The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res 68: pp. 5658-68 CrossRef
74. Chen, JT, Hasumi, K, Masubuchi, K (1992) Interferon-alpha, interferongamma and sizofiran in the adjuvant therapy in ovarian cancer鈥攁 preliminary trial. Biotherapy 5: pp. 275-80 CrossRef
75. Pujade-Lauraine, E, Guastalla, JP, Colombo, N, Devillier, P, Francois, E, Fumoleau, P (1996) Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 14: pp. 343-50
76. Windbichler, GH, Hausmaninger, H, Stummvoll, W, Graf, AH, Kainz, C, Lahodny, J (2000) Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82: pp. 1138-44 CrossRef
77. Freedman, RS, Kudelka, AP, Kavanagh, JJ, Verschraegen, C, Edwards, CL, Nash, M (2000) Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6: pp. 2268-78
78. Apte, SM, Vadhan-Raj, S, Cohen, L, Bassett, RL, Gordon, IO, Levenback, CF (2006) Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin. J Transl Med 4: pp. 16 CrossRef
79. Burke, F, East, N, Upton, C, Patel, K, Balkwill, FR (1997) Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat. Eur J Cancer 33: pp. 1114-21 CrossRef
80. Marth, C, Muller-Holzner, E, Greiter, E, Cronauer, MV, Zeimet, AG, Doppler, W (1990) Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 50: pp. 7037-41
81. Madiyalakan, R, Yang, R, Schultes, BC, Baum, RP, Noujaim, AA (1997) OVAREX MAb-B43.13: IFN-gamma could improve the ovarian tumor cell sensitivity to CA125-specific allogenic cytotoxic T cells. Hybridoma 16: pp. 41-5 CrossRef
82. Antony, GK, Dudek, AZ (2010) Interleukin 2 in cancer therapy. Curr Med Chem 17: pp. 3297-302 CrossRef
83. Recchia, F, Orio, F, Candeloro, G, Guerriero, G, Piazze, J, Rea, S (2010) Maintenance immunotherapy in recurrent ovarian cancer: long term follow-up of a phase II study. Gynecol Oncol 116: pp. 202-7 CrossRef
84. Vlad, AM, Budiu, RA, Lenzner, DE, Wang, Y, Thaller, JA, Colonello, K (2010) A phase II trial of intraperitoneal interleukin-2 in patients with platinumresistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 59: pp. 293-301 CrossRef
85. Perillo, A, Pierelli, L, Battaglia, A, Salerno, MG, Rutella, S, Cortesi, E (2002) Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Bone Marrow Transplant 30: pp. 571-8 CrossRef
86. Wei, S, Kryczek, I, Edwards, RP, Zou, L, Szeliga, W, Banerjee, M (2007) Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 67: pp. 7487-94 CrossRef
87. Lorusso, D, Scambia, G, Amadio, G, Legge, A, Pietragalla, A, Vincenzo, R (2012) Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br J Cancer 107: pp. 37-42 CrossRef
88. Simpkins, F, Flores, A, Chu, C, Berek, JS, Lucci, J, Murray, S (2013) Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res 1: pp. 168-78 CrossRef
89. Mirshahidi, S, Kramer, VG, Whitney, JB, Essono, S, Lee, S, Dranoff, G (2009) Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survival. Vaccine 27: pp. 1825-33 CrossRef
90. Odunsi, K, Matsuzaki, J, Karbach, J, Neumann, A, Mhawech-Fauceglia, P, Miller, A (2012) Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A 109: pp. 5797-802 CrossRef
91. Odunsi, K, Mtasuzaki, J, James, SR, Mhawech-Fauceglia, P, Tsuji, T, Miller, A (2014) Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res 2: pp. 37-49 CrossRef
92. Rahma, OE, Ashtar, E, Czystowska, M, Szajnik, ME, Wieckowski, E, Bernstein, S (2012) A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 61: pp. 373-84 CrossRef
93. Leffers, N, Vermeij, R, Hoogeboom, BN, Schulze, UR, Wolf, R, Hamming, IE (2012) Long-term clinical and immunological effects of p53-SLP(R) vaccine in patients with ovarian cancer. Int J Cancer 130: pp. 105-12 CrossRef
94. Karkada, M, Berinstein, NL, Mansour, M (2014) Therapeutic vaccines and cancer: focus on DPX-0907. Biologics 8: pp. 27-38
95. Suzuki, S, Shibata, K, Kikkawa, F, Nakatsura, T (2014) Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. Hum Vaccin Immunother 10: pp. 338-43 CrossRef
96. Gulley, JL, Arlen, PM, Tsang, KY, Yokokawa, J, Palena, C, Poole, DJ (2008) Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 14: pp. 3060-9 CrossRef
97. Mohebtash, M, Tsang, KY, Madan, RA, Huen, NY, Poole, DJ, Jochems, C (2011) A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res 17: pp. 7164-73 CrossRef
98. Palucka, K, Banchereau, J (2013) Dendritic-cell-based therapeutic cancer vaccines. Immunity 39: pp. 38-48 CrossRef
99. Chu, CS, Boyer, J, Schullery, DS, Gimotty, PA, Gamerman, V, Bender, J (2012) Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 61: pp. 629-41 CrossRef
100. Kandalaft, LE, Powell, DJ, Chiang, CL, Tanyi, J, Kim, S, Bosch, M (2013) Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2: pp. e22664 CrossRef
101. Baek, S, Kim, YM, Kim, SB, Kim, CS, Kwon, SW, Kim, Y (2015) Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial. Cell Mol Immunol 12: pp. 87-95 CrossRef
102. Gong, J, Nikrui, N, Chen, D, Koido, S, Wu, Z, Tanaka, Y (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 165: pp. 1705-11 CrossRef
103. Koido, S, Nikrui, N, Ohana, M, Xia, J, Tanaka, Y, Liu, C (2005) Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol 99: pp. 462-71 CrossRef
104. Kalos, M, June, CH (2013) Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: pp. 49-60 CrossRef
105. Wright, SE, Rewers-Felkins, KA, Quinlin, IS, Philips, CA, Townsend, M, Philip, R (2012) Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 35: pp. 196-204 CrossRef
106. Spear, P, Barber, A, Rynda-Apple, A, Sentman, CL (2013) NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 91: pp. 435-40 CrossRef
107. Kandalaft, LE, Powell, DJ, Coukos, G (2012) A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 10: pp. 157 CrossRef
108. Chan, WM, Rahman, MM, McFadden, G (2013) Oncolytic myxoma virus: the path to clinic. Vaccine 31: pp. 4252-8 CrossRef
109. Correa, RJ, Komar, M, Tong, JG, Sivapragasam, M, Rahman, MM, McFadden, G (2012) Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity. Gynecol Oncol 125: pp. 441-50 CrossRef
110. Hirasawa, K, Nishikawa, SG, Norman, KL, Alain, T, Kossakowska, A, Lee, PW (2002) Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: pp. 1696-701
111. Jennings, VA, Ilett, EJ, Scott, KJ, West, EJ, Vile, R, Pandha, H (2014) Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer 134: pp. 1091-101 CrossRef - 刊物主题：Oncology;
- 出版者：Springer US
- ISSN：1534-6277
文摘